QNRX
Quoin Pharmaceuticals, Ltd.
OpenVolumeMkt capP/EEPSDiv yield
Day – 52-wk –
Expected move
No implied move.
Next report
Last report
—
Largest filed tie
—
13F top-10 QoQ
Top fund weight
—
Quoin Pharmaceuticals, Ltd.
Expected move
No implied move.
Next report
Last report
—
Largest filed tie
—
13F top-10 QoQ
Top fund weight
—
Quoin Pharmaceuticals, Ltd.
3.94
+80.14%
shares held · 10 largest managers
No changes.
No changes.
| Manager | Value | % base | |
|---|---|---|---|
| Stonepine | $3.7M | 41.04% | +1332.00% |
| Dauntless Investment | $1.0M | 11.52% | +9.36% |
| Ikarian Capital | $1.0M | 11.34% | 0.00% |
| Millennium | $543,643 | 6.02% | +47.31% |
| SummitTX Capital | $485,452 | 5.38% | 0.00% |
| Manager | Value | % base | |
|---|---|---|---|
| Stonepine | $3.7M | 41.04% | +1332.00% |
| Dauntless Investment | $1.0M | 11.52% | +9.36% |
| Ikarian Capital | $1.0M | 11.34% | 0.00% |
| Millennium | $543,643 | 6.02% | +47.31% |
| SummitTX Capital | $485,452 | 5.38% | 0.00% |
No peers for Quoin Pharmaceuticals, Ltd. yet.
No peers for Quoin Pharmaceuticals, Ltd. yet.
Annual filing, covered
10-K parsed · Mar 26 '26
Supply-chain ties, covered
Disclosed · both directions
Fund holders, covered
No N-PORT holders
13F holdings, covered
13F quarter · Jun 30 '26
Management, not covered
Not covered · DEF 14A, 8-K 5.02
Company IR feed, not covered
News via newswires & EDGAR
Products, patents, hiring, not covered
Not covered
Annual filing, covered
10-K parsed · Mar 26 '26
Supply-chain ties, covered
Disclosed · both directions
Fund holders, covered
No N-PORT holders
13F holdings, covered
13F quarter · Jun 30 '26
Management, not covered
Not covered · DEF 14A, 8-K 5.02
Company IR feed, not covered
News via newswires & EDGAR
Products, patents, hiring, not covered
Not covered
Tall tick = annual report · Source: EDGAR
No thesis.
Quoin Pharmaceuticals, Ltd., a specialty pharmaceutical company, focuses on the development of therapeutic products for rare and orphan diseases. It offers QRX003, a topical lotion to treat Netherton Syndrome; QRX004 for the treatment dystrophic epidermolysis bullosa; and QRX006, a therapy to treat rare skin disease. The company was incorporated in 2018 and is based in Ashburn, Virginia.
Quoin Pharmaceuticals, Ltd., a specialty pharmaceutical company, focuses on the development of therapeutic products for rare and orphan diseases. It offers QRX003, a topical lotion to treat Netherton Syndrome; QRX004 for the treatment dystrophic epidermolysis bullosa; and QRX006, a therapy to treat rare skin disease. The company was incorporated in 2018 and is based in Ashburn, Virginia.
—
—